A new blood test can detect lung cancers, without relying on invasive procedures, by measuring the level of two proteins in patients’ blood. In a multicentre clinical trial, researchers from the Medical University of South Carolina (MUSC) have reported that this procedure is 98% effective in distinguishing benign and malignant lung nodules. Patients with high-risk lung nodules have to usually undergo invasive testing such as biopsy or surgery to remove such nodules. However, more than 75 to 80 percent of these nodules are usually benign.
The new blood test monitors the level of blood plasma marker LG3BP and C163A integrated with other predictors of cancer like age, size, and characteristics of the nodule. Clinical Trials The clinical trial, Pulmonary Nodule Plasma Proteomic Classifier (PANOPTIC) study was conducted on 685 patients who were over 40 years of age or older. These patients…
